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ABSTRACT 1 
 2 
Recent studies have suggested possible adverse effects of thiazolidinediones 3 
on bone metabolism.  However, the detailed mechanism by which the activity of 4 
PPAR affects bone formation has not been elucidated.  Impaired osteoblastic function 5 
due to cytokines is critical for the progression of inflammatory bone diseases.  In the 6 
present study we investigated the cellular mechanism by which PPAR actions interact 7 
with osteoblast differentiation regulated by BMP and TNF-α using mouse myoblastic 8 
C2C12 cells.  BMP-2 and -4 potently induced the expression of various bone 9 
differentiation markers including Runx2, osteocalcin, type-1 collagen and alkaline 10 
phosphatase (ALP) in C2C12 cells.  When administered in combination with a PPARα 11 
agonist (fenofibric acid) but not with a PPARγ agonist (pioglitazone), BMP-4 enhanced 12 
osteoblast differentiation through the activity of PPARα.  The osteoblastic changes 13 
induced by BMP-4 were readily suppressed by treatment with TNF-α.  Interestingly, 14 
the activities of PPARα and PPARγ agonists reversed the suppression by TNF-α of 15 
osteoblast differentiation induced by BMP-4.  Furthermore, TNF-α-induced 16 
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phosphorylation of MAPKs, NFκB, IκB and Stat pathways was inhibited in the 1 
presence of PPARα and PPARγ agonists with reducing TNF-α receptor expression.  In 2 
view of the finding that inhibition of SAPK/JNK, Stat and NFκB pathways reversed the 3 
TNF-α suppression of osteoblast differentiation, we conclude that these cascades are 4 
functionally involved in the actions of PPARs that antagonize TNF-α-induced 5 
suppression of osteoblast differentiation.  It was further discovered that the PPARα 6 
agonist enhanced BMP-4-induced Smad1/5/8 signaling through downregulation of 7 
inhibitory Smad6/7 expression, whereas the PPARγ agonist impaired this activity by 8 
suppressing BMPRII expression.  On the other hand, BMPs increased the expression 9 
levels of PPARα and PPARγ in the process of osteoblast differentiation.  Thus, PPARα 10 
actions promote BMP-induced osteoblast differentiation, while both activities of 11 
PPARα and PPARγ suppress TNF-α actions.  Collectively, our present data establishes 12 
that PPAR activities are functionally involved in modulating the interaction between the 13 
BMP system and TNF-α receptor signaling that is crucial for bone metabolism. 14 
15 
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INTRODUCTION 1 
 2 
Bone morphogenetic proteins (BMPs), members of the transforming growth 3 
factor (TGF)-β superfamily, play pivotal regulatory roles in mesoderm induction and 4 
dorso-ventral patterning of developing limb buds and are known to promote 5 
differentiation of mesenchymal stem cells into chondrocytes and osteoblasts as well as 6 
differentiation of osteoprogenitor cells into osteoblasts (Lieberman et al., 2002).  7 
BMPs are also known to have critical roles in governing various aspects of 8 
embryological development, including development of the brain, heart, kidney and eyes 9 
(Reddi, 1997).  In addition to the developmental actions of BMPs, various 10 
physiological actions of BMPs in endocrine and vascular tissues have recently been 11 
elucidated (Shimasaki et al., 2004; Otsuka, 2010; Otsuka et al., 2011).  The biological 12 
functions of BMPs are mediated through the Smad signal transduction pathway via 13 
specific combinations of the proper BMP receptors (Shimasaki et al., 2004). 14 
Osteoblast differentiation is a complex process regulated by various endocrine, 15 
paracrine and autocrine factors.  Osteoblasts, which arise from mesenchymal stem cell 16 
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precursors, undergo differentiation in response to a number of factors, including BMPs, 1 
TGFs, insulin-like growth factor-I (IGF-I), vascular endothelial growth factor (VEGF), 2 
and steroids (McCarthy et al., 1989; Celeste et al., 1990; Midy and Plouet, 1994; 3 
Hughes et al., 1995; Spelsberg et al., 1999).  Once matrix synthesis begins in cultured 4 
osteoblast cells, the cells differentiate and osteoblastic markers, including alkaline 5 
phosphatase (ALP), type-I collagen and osteocalcin, are subsequently activated.  6 
Osteoblasts then embed in the extracellular matrix consisting of collagen fibrils, and the 7 
matrix is mineralized and extended in collagen fibrils.  Deposition and maintenance of 8 
mineralized skeletal elements are further regulated by various growth factors including 9 
BMPs and cytokines such as interleukins and tumor necrosis factors (TNFs).  10 
 Among the various cytokines, TNF-α receptor signaling plays a predominant 11 
role in bone loss in arthritis.  TNF-α is also involved in controlling osteoblast survival 12 
and function in addition to the induction of osteoclast differentiation leading to bone 13 
resorption (Kudo et al., 2002).  The effectiveness of blocking TNF-α actions in 14 
treatment of active rheumatoid arthritis established the clinical significance of TNF-α in 15 
the pathogenesis of inflammatory bone diseases (Feldmann and Maini, 2001; Scott and 16 
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Kingsley, 2006).  However, the underlying mechanism of TNF-α in the regulation of 1 
differentiation of osteoblasts has not been fully elucidated.   2 
Peroxisome proliferator-activated receptors (PPARs) including PPARα, 3 
PPARβ/δ and PPARγ are categorized to the family of nuclear hormone receptors 4 
(Desvergne and Wahli, 1999).  PPARγ is activated by natural ligands such as 5 
polyunsaturated fatty acids and metabolites of prostaglandins and synthetic ligands, 6 
thiazolidinediones, such as rosiglitazone, pioglitazone and troglitazone (Willson et al., 7 
2000).  Recent studies have provided evidence that PPARγ activity may directly 8 
inhibit bone formation by diverting mesenchymal stem cells from the osteogenic 9 
process to the adipocytic lineage (Grey, 2008).  Clinical studies have also revealed that 10 
thiazolidinediones decrease markers of bone formation with reduction in bone mass and 11 
increase in fracture incidence in women (Grey et al., 2007; Grey, 2008).  However, the 12 
underlying mechanism by which PPARs affect osteoblastic differentiation has yet to be 13 
clarified.   14 
The pluripotent mesenchymal precursor cell line, C2C12, a subclone of a 15 
mouse myoblastic cell line, has been widely used as a model to investigate the early 16 
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stages of osteoblast differentiation during bone formation in muscular tissues.  1 
Treatment of C2C12 cells with various TGF-β superfamily ligands has distinct effects 2 
on differentiation, and BMPs inhibit myoblast differentiation of C2C12 cells and 3 
promote osteoblastic cell differentiation (Katagiri et al., 1994; Ebisawa et al., 1999).  4 
In the present study, we investigated the cellular mechanisms by which PPAR agonists 5 
interact in the process of osteoblastic differentiation regulated by the activation of BMP 6 
and TNF-α with a focus on the interaction between BMP-Smad and PPAR signaling.  7 
8 
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MATERIALS AND METHODS 1 
 2 
Reagents and supplies 3 
Dulbecco’s Modified Eagle’s Medium, penicillin-streptomycin solution, 4 
dimethylsulfoxide (DMSO), and the PPARα antagonist GW6471 were purchased from 5 
Sigma-Aldrich Co. Ltd. (St. Louis, MO).  Recombinant human TNF-α was obtained 6 
from PeproTech EC Ltd. (London, UK).  Recombinant human BMP-2, -4, -6 and -7 7 
were purchased from R&D Systems, Inc. (Minneapolis, MN); ERK inhibitor U0126 and 8 
p38-MAPK inhibitor SB203580 were from Promega Corp. (Madison, WI); SAPK/JNK 9 
inhibitor SP600125 was from Biomol Lab. Inc. (Plymouth Meeting, PA); and the JAK 10 
family tyrosine kinase inhibitor AG490, Akt inhibitor SH-5 and NFκB activation 11 
inhibitor IV were from Calbiochem (San Diego, CA).  Plasmids of BRE-Luc and 12 
Id-1-Luc were kindly provided by Drs. Tetsuro Watabe and Kohei Miyazono, Tokyo 13 
University, Japan.  The PPARα agonist fenofibric acid and the PPARγ agonist 14 
pioglitazone were provided by Kaken Pharmaceutical Co. Ltd. (Tokyo, Japan) and 15 
Takeda Chemical Industries (Osaka, Japan), respectively. 16 
MCE-D-11-00220R 
Revised version 
Takano and Otsuka et al. 
 - 9 - 
 1 
Cell culture and morphological examination 2 
The mouse myoblast cell line C2C12 was obtained from American Type Culture 3 
Collection (Manassas, VA).  C2C12 cells were cultured in DMEM supplemented with 4 
10% fetal calf serum (FCS) and penicillin-streptomycin solution at 37°C under a humid 5 
atmosphere of 95% air/5% CO2.  Changes in cell morphology were monitored using an 6 
inverted microscope.  7 
 8 
RNA extraction, RT-PCR, and quantitative real-time PCR analysis 9 
To prepare total cellular RNA, C2C12 cells were cultured in a 12-well plate (1 × 105 10 
viable cells/well) and treated with the indicated concentrations of TNF-α and BMPs in 11 
combination with a PPARα agonist (fenofibric acid), a PPARγ agonist (pioglitazone) 12 
and various inhibitors including GW6471, U0126, SB203580, SP600125, AG490, 13 
NFκB inhibitor and SH-5 in serum-free DMEM.  After 48-h culture, the medium was 14 
removed, and total cellular RNA was extracted using TRIzol® (Invitrogen Corp., 15 
Carlsbad, CA), quantified by measuring absorbance at 260 nm.  The extracted RNA 16 
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(1.0 μg) was subjected to an RT reaction using the First-Strand cDNA synthesis 1 
system® (Invitrogen Corp.) with random hexamer (50 ng/μl), reverse transcriptase (200 2 
U), and deoxynucleotide triphosphate (2.5 mM) at 42°C for 55 min and at 70°C for 10 3 
min.  Subsequently, hot-start PCR was performed using MgCl2 (50 mM), 4 
deoxynucleotide triphosphate (2.5 mM), and 1.5 U of Taq DNA polymerase (Invitrogen 5 
Corp.) under the conditions we previously reported (Mukai et al., 2007; Matsumoto et 6 
al., 2010).  PCR primer pairs, custom-ordered from Invitrogen Corp., were selected 7 
from different exons of the corresponding genes as follows: PPARα, 1769-1789 and 8 
1950-1969 (from NM_011144); PPARγ, 567-588 and 838-858 (from NM_011146); Id-1, 9 
225-247 and 364-384 (from NM_010495); runt-related transcription factor 2 (Runx2), 10 
1041-1062 and 1379-1400 (from NM_009820); osteocalcin, 125-144 and 312-331 11 
(NM_007541); type-1 collagen (collagen-1), 3872-3891 and 3922-3941 (NM_007742); 12 
ALP, 1365-1385 and 1549-1568 (NM_007431); TNFR1, 931-951 and 1211-1231 13 
(BC052675); TNFR2, 142-162 and 1142-1162 (Y14622); and a house-keeping gene, 14 
ribosomal protein L19 (RPL19), 373-393 and 547-567 (from NM_009078).  Primer 15 
pairs for mouse BMP type-1 and type-2 receptors and Smads were selected as we 16 
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reported previously (Otani et al., 2007; Takeda et al., 2007).  The expression of 1 
PPARα, PPARγ and RPL19 mRNAs was detected by RT-PCR analysis.  Aliquots of 2 
PCR products were electrophoresed on 1.5% agarose gels and visualized after ethidium 3 
bromide staining.  For the quantification of mRNA levels of PPARs, Runx2, 4 
osteocalcin, collagen-1, ALP, TNFRs, BMP receptors, Smads and Id-1, real-time PCR 5 
was performed using the StepOnePlus® real-time PCR system (Applied Biosystems, 6 
Foster City, CA) under optimized annealing conditions, following the manufacturer’s 7 
protocol with the following profile: 40 cycles each at 95°C for 3 sec and 60-62°C for 30 8 
sec.  The threshold cycle (Ct) values were calculated using the StepOnePlus™ system 9 
software (Applied Biosystems).  The relative expression of each mRNA was calculated 10 
by the ΔCt method, in which ΔCt is the value obtained by subtracting the Ct value of 11 
RPL19 mRNA from the Ct value of the target mRNA, and the amount of target mRNA 12 
relative to RLP19 mRNA was expressed as 2-(ΔCt).  The data are expressed as the ratio 13 
of target mRNA to RPL19 mRNA. 14 
 15 
Western immunoblot analysis 16 
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Cells (1 × 105 viable cells/well) were precultured in 12-well plates in DMEM 1 
containing 10% FCS for 24 h.  After preculture, the medium was replaced with 2 
serum-free fresh medium, and then cells were treated with the indicated concentrations 3 
of the PPARα agonist (fenofibric acid) and PPARγ agonist (pioglitazone) for 24 h 4 
before addition of TNF-α and BMP-4.  After stimulation with growth factors for 15 5 
and 60 min, cells were solubilized in 100 μl RIPA lysis buffer (Upstate Biotechnology, 6 
Inc., Lake Placid, NY) containing 1 mM Na3VO4, 1 mM sodium fluoride, 2% sodium 7 
dodecyl sulfate, and 4% β-mercaptoethanol.  For detecting protein expression of 8 
PPARα and PPARγ, cell lysates were collected from cells treated with BMP-4 for 48 h 9 
and 72 h.  For detecting protein expression of TNFRs, cell lysates were collected from 10 
cells treated with PPARα and PPARγ agonists for 48 h.  The cell lysates were then 11 
subjected to SDS-PAGE/immunoblotting analysis as we previously reported using 12 
anti-phospho-Smad1/5/8 antibody (Cell Signaling Technology, Inc., Beverly, MA), 13 
anti-phospho- and anti-total-extracellular signal-regulated kinase (ERK) 1/2 MAPK 14 
antibodies (Cell Signaling Technology, Inc.), anti-phospho- and anti-total-p38 MAPK 15 
antibodies (Cell Signaling Technology, Inc.), anti-phospho- and 16 
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anti-total-stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) 1 
MAPK antibodies (Cell Signaling Technology, Inc.), anti-phospho- and anti-total 2 
NFκB-p65 antibodies, and anti-phospho- and anti-total IκB-α antibodies (Cell 3 
Signaling Technology, Inc.), anti-phospho- and anti-total-Stat3 and Stat5 antibodies 4 
(Cell Signaling Technology, Inc.), anti-phospho- and anti-total-Akt antibodies (Cell 5 
Signaling Technology, Inc.), anti-PPARα (H-98) and anti-PPARγ (H-100) antibodies 6 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-TNFR1 (H-271) and 7 
anti-TNFR2 (H-202) antibodies (Santa Cruz Biotechnology, Inc.), and anti-actin 8 
antibody (Sigma-Aldrich Co. Ltd.).  The relative integrated density of each protein 9 
band was digitized by NIH image J 1.34s. 10 
 11 
Transient transfection and luciferase assay 12 
C2C12 cells (5 × 104 viable cells) were precultured in 12-well plates in DMEM with 13 
10% FCS.  The cells were then transiently transfected with 500 ng of BRE-Luc or 14 
Id-1-Luc reporter plasmids and 50 ng of cytomegalovirus-β-galactosidase plasmid 15 
(pCMV-β-gal) using FuGENE 6 (Roche Molecular Biochemicals, Indianapolis, IN) for 16 
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12 h.  The cells were then treated with the indicated concentrations of PPARα and 1 
PPARγ agonists in combination with BMP-4 in serum-free fresh medium for 24 h.  2 
The cells were washed with PBS and lysed with Cell Culture Lysis Reagent (Toyobo, 3 
Osaka, Japan).  Luciferase activity and β-galactosidase (β-gal) activity of the cell 4 
lysate were measured by luminescencer-PSN (ATTO, Tokyo, Japan).  The data are 5 
shown as the ratio of luciferase to β-gal activity.  6 
 7 
Statistical analysis 8 
All results are shown as means ± SEM of data from at least three separate experiments, 9 
each performed with triplicate samples.  Differences between groups were analyzed 10 
for statistical significance using ANOVA with Fisher’s protected least significant 11 
difference (PLSD) test or unpaired t-test, when appropriate, to determine differences 12 
(StatView 5.0 software, Abacus Concepts, Inc., Berkeley, CA).  P values < 0.05 were 13 
accepted as statistically significant. 14 
 15 
16 
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RESULTS 1 
 2 
We first examined the effects of PPAR agonists on BMP-induced osteoblastic 3 
differentiation of C2C12 cells.  BMP ligands including BMP-2, -4, -6 and -7 (100 4 
ng/ml) facilitated osteoblastic differentiation of C2C12 cells for 48 h as demonstrated 5 
by the increased expression levels of Runx2, osteocalcin and type-1 collagen 6 
(collagen-1) mRNAs (Fig. 1A).  BMP-2 and -4 (100 ng/ml) stimulated the expression 7 
of these bone differentiation markers more effectively than did the same concentrations 8 
of BMP-6 and -7.  Of note, the presence of a PPARα agonist (fenofibric acid, 3 μM), 9 
but not a PPARγ agonist (pioglitazone, 3 μM), significantly enhanced osteoblast 10 
differentiation induced by BMP-4 (100 ng/ml) (Fig. 1A).   11 
To know whether the effects of PPARα agonist (fenofibric acid) on enhancing 12 
BMP-4-induced osteoblast differentiation occurred through PPARα, a specific 13 
antagonist of PPARα, GW6471, was used in the same culture conditions.  As shown in 14 
Fig. 1B, the effects of PPARα agonist (3 μM) on Runx2 and collagen-1 expression 15 
induced by BMP-4 (100 ng/ml) were reversed in the presence of GW6471 (1 to 10 μM) 16 
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concentration dependently. 1 
To elucidate the mechanism by which PPAR agonists modulate the expression 2 
levels of osteoblastic markers in C2C12 cells, effects of PPAR agonists on BMP 3 
receptor signaling were subsequently examined.  It was found that the PPARα agonist 4 
(3 μM) significantly enhanced promoter activity of the BMP-responsive element 5 
represented by BRE-Luc activity induced by BMP-4 (100 ng/ml) (Fig. 1C).  In 6 
contrast, the PPARγ agonist (3 μM) reduced BRE-Luc activity induced by BMP-4 (100 7 
ng/ml) (Fig. 1C).  Similar results were obtained by a promoter assay using the BMP 8 
target gene Id-1-Luc (data not shown).  Furthermore, the PPARα agonist (3 μM) 9 
significantly reduced mRNA levels of inhibitory Smad6 and Smad7, while treatment 10 
with the PPARγ agonist (3 μM) decreased the expression level of BMPRII mRNA in 11 
C2C12 cells (Fig. 1D).  With regard to the BMP receptor system, several preferential 12 
combinations of BMP ligands and receptors have been recognized to date (Shimasaki et 13 
al., 2004).  BMP-2 and -4 most readily bind to ALK-3 and/or ALK-6 in combination 14 
with the type-2 receptor BMPRII.  Since ALK-6 is not expressed in C2C12 cells 15 
(Mukai et al., 2007), the major functional complex for the osteoblastic differentiation 16 
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induced by BMP-4 is likely ALK-3/BMPRII.  Thus, PPARγ activity was found to 1 
suppress BMP-Smad signaling by inhibiting BMPRII expression, whereas PPARα 2 
enhanced BMP receptor signaling by suppressing inhibitory Smad6/7.  On the other 3 
hand, BMP-2, -4, -6 and -7 (100 ng/ml) induced increases in mRNA levels of PPARα 4 
and PPARγ in C2C12 cells cultured for 48 h (Fig. 1E).  It was also found that BMP-4 5 
(100 ng/ml) stimulated the expression of PPARα and PPARγ protein levels in 48 h to 72 6 
h cultures (Fig. 1F).   7 
We next studied the effects of PPAR activities on the interaction between 8 
BMP and TNF-α in C2C12 cells.  Osteoblastic differentiation induced by BMP-2, -4, 9 
-6 and -7 (100 ng/ml) was suppressed by co-treatment with TNF-α (10 ng/ml), with the 10 
most pronounced effects on BMP-2- and BMP-4-induced differentiation (Fig. 2A).  11 
Importantly, the inhibitory effects of TNF-α (10 ng/ml) on BMP-4 (100 ng/ml)-induced 12 
mRNA expression of osteoblastic markers including Runx2, osteocalcin and collagen-1 13 
were reversed by co-treatment with PPARα and PPARγ agonists (3 μM), although the 14 
impact of PPARγ agonist on TNF-α inhibition of BMP-4-induced ALP expression was 15 
not significant (Fig. 2B).  Smad1/5/8 phosphorylation induced by BMP-4 (100 ng/ml) 16 
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was suppressed by treatment with TNF-α (100 ng/ml) (Fig. 2C).  Of note, the 1 
inhibitory actions of TNF-α (10 ng/ml) on BMP-induced Smad1/5/8 phosphorylation 2 
were reversed in the presence of either the PPARα or PPARγ agonist (3 μM) (Fig. 2C).  3 
In accordance with the results for Smad phosphorylation, suppression by TNF-α (10 4 
ng/ml) of BMP target gene Id-1 transcription induced by BMP-4 was also partially 5 
reversed by co-treatment with PPARα and PPARγ agonists (3 μM) (Fig. 2D).  The 6 
effects of TNF-α are mediated through two distinct receptors: type 1, also called 7 
p60/p55 receptor (TNFR1), and type 2, also called p80/p75 receptor (TNFR2) (Grell et 8 
al., 1994).  PPARα and PPARγ agonists (3 μM) decreased the expression levels of 9 
TNFR1 and TNFR2 mRNAs (Fig. 2E).  In addition, the changes in TNFR expression 10 
by PPARα and PPARγ agonist (3 μM) were evaluated by immunoblot analysis using 11 
anti-TNFR1 and TNFR2 antibodies, showing that the protein level of TNFR2 was also 12 
decreased by treatments with PPARα and PPARγ agonists (Fig. 2F).  The mechanism 13 
by which PPARα/γ activities reduced TNF-α actions may be contributed to the 14 
downregulation of TNFR signaling in C2C12 cells.  Thus, both actions of PPARα and 15 
PPARγ agonists antagonize suppression by TNF-α of osteoblastic differentiation 16 
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induced by BMP-4 with restoration of TNF-α-induced suppression of Smad1/5/8 1 
phosphorylation and Id-1 transcription.   2 
Subsequently, the effects of PPARα and PPARγ agonists on TNF-α-induced 3 
cellular signaling were investigated.  TNF-α (100 ng/ml) readily stimulated MAPK 4 
phosphorylation including ERK1/ERK2, p38-MAPK, SAPK/JNK pathways in C2C12 5 
cells (Fig. 3A).  The TNF-α actions were not significantly altered by treatment with 6 
BMP-4 (100 ng/ml).  Notably, TNF-α (100 ng/ml)-induced phosphorylation of 7 
MAPKs including p38-MAPK and SAPK/JNK pathways (Fig. 3A) was inhibited in the 8 
presence of either the PPARα or PPARγ agonist (3 μM).  NFκB, IκB and Stat3 9 
pathways were also stimulated by TNF-α (100 ng/ml), and the stimulation of these 10 
pathways was not affected by co-treatment with BMP-4 (100 ng/ml) (Fig. 3B).  11 
TNF-α-induced activation of NFκB signaling was significantly suppressed by the 12 
PPARγ agonist (3 μM), while IκB and Stat3 phoshorylation induced by TNF-α was 13 
inhibited by either the PPARα or PPARγ agonist (3 μM).  The Akt pathway was also 14 
stimulated by TNF-α (100 ng/ml); however, PPARα or PPARγ agonist (3 μM) failed to 15 
suppress Akt phosphorylation (Fig. 3B).   16 
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To further explore the major pathways for TNF-α receptor signaling in 1 
BMP-4-induced osteoblastic differentiation, cells were treated with specific inhibitors 2 
for ERK1/ERK2, p38-MAPK SAPK/JNK, Stat and NFκB.  Inhibition of SAPK/JNK, 3 
Stat and NFκB pathways with SP600125, AG490 and NFκB inhibitor, respectively, 4 
reversed the suppression by TNF-α (10 ng/ml) of Runx2 (Fig. 4A) and osteocalcin (Fig. 5 
4B) mRNA expression induced by BMP-4 (100 ng/ml).  On the other hand, 6 
ERK1/ERK2 and p38 inhibition by U0126 and SB203580, respectively, failed to restore 7 
the suppression by TNF-α (10 ng/ml) of Runx2 (Fig. 4A) and osteocalcin (Fig. 4B) 8 
mRNA levels amplified by BMP-4 (100 ng/ml).  We thus conclude that SAPK/JNK, 9 
Stat and NFκB signaling plays an important role in PPARα and PPARγ antagonizing the 10 
suppression by TNF-α of osteoblastic differentiation. 11 
12 
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DISCUSSION 1 
 2 
In the present study, we investigated the cellular mechanism by which PPAR 3 
agonists interact in osteoblastic differentiation regulated by BMP-4 and TNF-α using 4 
mouse myoblastic C2C12 cells.  It was found that a PPARα agonist, fenofibric acid, 5 
stimulated BMP-4-induced osteoblastic differentiation through the PPARα activity.  Of 6 
note, PPARα agonist was revealed to enhance BMP-4 receptor signaling by suppression 7 
of inhibitory Smad6/7 expression.  TNF-α-induced SAPK/JNK, NFκB and Stat 8 
activation, which led to the inhibition of osteoblastic differentiation, was in turn 9 
inhibited by treatment with PPARα and PPARγ agonists.  The present results 10 
demonstrate that PPARα actions promote osteoblastic differentiation induced by BMP-4, 11 
while both activities of PPARα and PPARγ are effective in suppressing TNF-α actions.  12 
In addition, BMPs also increased the sensitivity of PPAR agonists by upregulating the 13 
expression of PPARα and PPARγ in the process of osteoblastic differentiation.  Hence, 14 
PPAR activities are functionally involved in modulating the interaction between BMP 15 
and TNF-α signaling, which is a key factor for osteoblastic differentiation (Fig. 5).   16 
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Although no bone abnormalities were identified in PPARα knockout mice 1 
(Wu et al., 2000), there is substantial evidence that PPARα has activities in bone 2 
development and in bone metabolism (Lecka-Czernik (Curr Osteoporos Rep 8: 84-90, 3 
2010) provides a comprehensive review of relevant literature (Lecka-Czernik, 2010)).  4 
In particular, the collective data suggests that PPARα may regulate bone metabolism 5 
and bone marrow conditions by providing energy through fatty acid oxidation and by 6 
controlling cell commitment within hematopoietic lineages rather than affecting the 7 
differentiation of bone cells (Lecka-Czernik, 2010).  Based on our present data, 8 
PPARα has beneficial effects, at least in part, in the early process of osteoblastic 9 
differentiation preferentially in combination with the activity of BMP-4, and both 10 
PPARα and PPARγ elicit anti-TNFα actions in the process of osteoblast differentiation.   11 
PPARγ is a critical transcription factor for the induction of adipocyte 12 
differentiation based on the experimental and clinical studies using PPARγ agonists, 13 
thiazolidinediones (Grey, 2008).  PPARγ transcripts are expressed in osteoblasts 14 
(Johnson et al., 1999; Jackson and Demer, 2000; Jeon et al., 2003) and osteoclast 15 
precursors (Mbalaviele et al., 2000; Chan et al., 2007).  PPARγ agonists promote 16 
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adipogenesis instead of osteoblastogenesis in vitro (Gimble et al., 1996).  PPARγ 1 
heterozygous-deficient mice demonstrate increased bone mass by stimulating 2 
osteoblastogenesis (Akune et al., 2004).  Taken together, it appears that PPARγ activity 3 
preferentially promotes adipogenetic cascade instead of the process of 4 
osteoblastogenesis.  In the present study, PPARγ activity was found to decrease 5 
Smad1/5/8 and its downstream signaling induced by BMP-4 by suppressing BMPRII 6 
expression in C2C12 cells, suggesting an inhibitory role of PPARγ activity in the early 7 
process of BMP-induced osteoblastic differentiation.  However, the activity of PPARγ 8 
did not seem likely enough to attain the biological inhibition of BMP-induced osteoblast 9 
differentiation evaluated by the levels of Runx2, osteocalcin and collagen-1 expression.  10 
The interaction between PPAR and BMPs may be involved in the dual actions of 11 
adipogenesis and osteogenesis by BMPs.  According to an analysis of BMPs on the 12 
mesenchymal stem cell differentiation, BMP-2, -4, -6, -7 and -9 activated adipogenic 13 
and osteogenic differentiation of mesenchymal stem cells (Kang et al., 2009).  14 
Interestingly, overexpression of PPARγ2 facilitated both osteogenic and adipogenic 15 
differentiation and PPARγ2 knockdown inhibited not only adipogenic differentiation but 16 
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also BMP-induced ossification (Kang et al., 2009), suggesting that PPARγ activity is 1 
also, at least in part, involved in promoting osteogenic differentiation. 2 
Imbalanced functions of osteoclasts and osteoblasts lead to bone damage seen 3 
in patients with inflammatory bone diseases such as rheumatoid arthritis.  Since bone 4 
loss in arthritis is related to activation of the TNF-α system, it can be hypothesized that 5 
TNF-α directly controls osteoblast survival and/or function in addition to its induction 6 
of osteoclast differentiation leading to excess bone resorption (Kudo et al., 2002).  In 7 
this regard, we previously reported that TNF-α suppresses BMP-2-induced expression 8 
of osteoblast markers such as Runx2, osteocalcin and ALP (Mukai et al., 2007), in 9 
which MAPK and NFκB are involved in the suppression by TNF-α of BMP-2 activity 10 
in C2C12 cells (Mukai et al., 2007; Yamashita et al., 2008; Matsumoto et al., 2010).  11 
The present results further demonstrated that, among BMP ligands, BMP-4 most 12 
effectively augments PPARα activity leading to promotion of osteoblastic 13 
differentiation.  BMP-4 also increased the sensitivity of PPAR agonists by 14 
upregulating the expression of PPARα and PPARγ in the process of osteoblastic 15 
differentiation.  Moreover, the activities of PPARα and PPARγ are involved in 16 
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antagonizing the TNF-α signaling that is a negative factor for osteoblastic 1 
differentiation induced by BMP-4. 2 
In our earlier study, the expression of other nuclear receptors such as estrogen 3 
receptors (ERα and ERβ) and glucocorticoid receptor (GCR) in C2C12 cells was 4 
significantly increased by BMP-2 stimulation (Matsumoto et al., 2010).  BMP-2 5 
increased the sensitivities of ERs and GCR, whereas estrogen and glucocorticoid 6 
differentially regulated BMP-Smad signaling, and these steroids antagonized TNF-α 7 
signaling in a different manner (Matsumoto et al., 2010).  In the present study, in 8 
addition to ER and GCR actions, PPARs were also found to antagonize TNF-α activities 9 
in osteoblastic differentiation.  Further studies are needed to utilize the efficacious 10 
actions of PPARα but modulate PPARγ activity in osteoblasts in relation to the activities 11 
of other nuclear receptor family molecules. 12 
Collectively, PPARs are functionally involved in the process of osteoblast 13 
differentiation directed by BMP-4 and TNF-α.  BMP-4 increases the sensitivities of 14 
PPARs, PPARα in turn upregulates and PPARγ represses BMP-Smad signaling, and 15 
PPARs antagonize TNF-α signaling in a different manner (Fig. 5).  Understanding the 16 
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integrated mechanisms behind BMP- and TNF-α-regulated osteoblastic differentiation 1 
may lead to the development of novel therapeutic strategies for osteoporosis and/or 2 
inflammatory bone disorders. 3 
 4 
5 
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FIGURE LEGENDS  1 
 2 
Fig. 1.  Effects of PPARα and PPARγ agonists on BMP-induced osteoblast 3 
differentiation.  A) After preculture, C2C12 cells were treated with BMP-2, -4, -6 and 4 
-7 (100 ng/ml) in combination with PPARα and PPARγ agonists (3 μM) for 48 h.  5 
Total cellular RNA was extracted and then subjected to PCR reaction.  Real-time PCR 6 
analysis was performed for quantification of Runx2, osteocalcin and collagen-1 mRNA 7 
levels.  The expression levels of target genes were standardized by RPL19 level in 8 
each sample.  B) Cells were treated with BMP-4 (100 ng/ml) in combination with 9 
PPARα agonist (3 μM) and the PPARα antagonist GW6471 (1 to 10 μM) for 48 h.  10 
Total cellular RNA was extracted and then subjected to real-time PCR analysis for 11 
quantification of Runx2 and collagen-1 mRNA levels.  The expression levels of target 12 
genes were standardized by RPL19 level in each sample.  C) Cells were transiently 13 
transfected with BRE-Luc reporter plasmid (500 ng) and pCMV-β-gal.  The cells were 14 
then treated with BMP-4 (100 ng/ml) and with PPARα and PPARγ agonists (3 μM) for 15 
24 h.  The cells were lysed and the luciferase activity and β-galactosidase (β-gal) 16 
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activity were measured by a luminometer.  The data were expressed as the ratio of 1 
luciferase to β-gal activity.  D) Cells were treated with PPARα and PPARγ agonists (3 2 
μM) for 48 h, and total cellular RNA was extracted.  Real-time PCR analysis was 3 
performed for quantification of BMPRII, ActRII, ALK-2, ALK-3, Smad6 and Smad7 4 
mRNA levels.  The expression levels of target genes were standardized by RPL19 5 
level in each sample.  E) Cells were treated with BMP-2, -4, -6 and -7 (100 ng/ml) for 6 
48 h, and total cellular RNA was extracted.  Real-time PCR analysis was performed 7 
for quantification of PPARα and PPARγ mRNA levels.  The expression levels of target 8 
genes were standardized by RPL19 level in each sample.  F) For protein analysis, cells 9 
were treated with BMP-4 (100 ng/ml) for 48 h and 72 h.  The cells were then lysed and 10 
subjected to SDS-PAGE/immunoblot (IB) analysis using antibodies that detect PPARα 11 
and PPARγ, and actin as an internal control.  Results (A-E) are shown as means ± 12 
SEM of data from at least three separate experiments, each performed with triplicate 13 
samples.  The results (F) shown are representative of those obtained from three 14 
independent experiments.  The results were analyzed by ANOVA with Fisher’s post 15 
hoc test (A-E).  For each result within a panel, *, P < 0.05 vs. control in each set of 16 
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comparisons or between the indicated groups; and the values with different superscript 1 
letters are significantly different at P < 0.05. 2 
 3 
Fig. 2.  Effects of TNF-α and PPARα and PPARγ agonists on BMP-induced 4 
osteoblast differentiation and TNF receptor (TNFR) expression in C2C12 cells.  A, 5 
B) After preculture, the cells were treated with BMP-2, -4, -6 and -7 (100 ng/ml), 6 
TNF-α (10 ng/ml), and PPARα and PPARγ agonists (3 μM) for 48 h.  Total cellular 7 
RNA was extracted and subjected to PCR reaction.  Real-time PCR analysis was 8 
performed for quantification of Runx2, osteocalcin, collagen-1 and ALP mRNA levels.  9 
The expression levels of target genes were standardized by RPL19 level in each sample.  10 
C) After preculture, the cells were pretreated with PPARα and PPARγ agonists (3 μM) 11 
for 24 h prior to addition of BMP-2 (100 ng/ml) and TNF-α (100 ng/ml).  After 12 
60-min culture, the cells were lysed and subjected to SDS-PAGE/immunoblot (IB) 13 
analysis using antibodies that detect phosphorylated Smad1/5/8 (pSmad1/5/8) and actin 14 
as an internal control.  The results shown are representative of those obtained from 15 
three independent experiments.  The relative integrated density of each protein band 16 
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was digitized by NIH image J 1.34s, pSmad1/5/8 levels were normalized by actin levels 1 
in each sample, and then pSmad1/5/8 levels after 60-min stimulation were expressed as 2 
fold changes.  D) Cells were treated with BMP-4 (100 ng/ml) and TNF-α (10 ng/ml) in 3 
combination with PPARα and PPARγ agonists (3 μM) for 48 h and total RNA was 4 
extracted.  Real-time PCR analysis was performed for the quantification of Id-1 5 
mRNA levels.  The expression levels of target genes were standardized by RPL19 6 
level in each sample.  E) Cells were treated with PPARα and PPARγ agonists (3 μM) 7 
for 48 h and total RNA was extracted.  Real-time PCR analysis was performed for 8 
quantification of TNFR1 and TNFR2 mRNA levels.  The expression levels of target 9 
genes were standardized by RPL19 level in each sample.  F) For protein analysis, cells 10 
were treated with PPARα and PPARγ agonists (3 μM) for 48 h.  The cells were then 11 
lysed and subjected to SDS-PAGE/immunoblot (IB) analysis using antibodies that 12 
detect TNFR1 and TNFR2, and actin as an internal control.  The results shown are 13 
representative of those obtained from three independent experiments.  Results (A-E) 14 
are shown as means ± SEM of data from at least three separate experiments, each 15 
performed with triplicate samples.  The results were analyzed by the unpaired t-test 16 
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(A) or ANOVA with Fisher’s post hoc test (B-E).  For each result within a panel, *, P 1 
< 0.05 vs. control in each set of comparisons; and the values with different superscript 2 
letters are significantly different at P < 0.05. 3 
 4 
Fig. 3.  Effects of BMP-4 and PPARα and PPARγ agonists on TNF-α-induced 5 
MAPK, NFκB, IκB, Stat and Akt activation in C2C12 cells.  A, B) After preculture, 6 
cells were treated with PPARα and PPARγ agonists (3 μM) for 24 h prior to addition of 7 
BMP-4 (100 ng/ml) and TNF-α (100 ng/ml).  After 15- and 60-min culture, cells were 8 
lysed and subjected to SDS-PAGE/immunoblot (IB) analysis using anti-phospho- and 9 
anti-total-ERK1/ERK2 (pERK and tERK) antibodies, anti-phospho- and anti-total-p38 10 
(pP38 and tP38) antibodies, anti-phospho- and anti-total-SAPK/JNK (pJNK and tJNK) 11 
antibodies, anti-phospho- and anti-total-NFκB-p65 (pNFκB and tNFκB) antibodies, 12 
anti-phospho- and anti-total-IκB (pIκB and tIκB) antibodies, anti-phospho- and 13 
anti-total-Stat3 (pStat3 and tStat3) antibodies, and anti-phospho- and anti-total-Akt 14 
(pAkt and tAkt) antibodies.  The results (A, B) shown are representative of those 15 
obtained from three independent experiments.  The relative integrated density of each 16 
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protein band was digitized by NIH image J 1.34s and shown as phospho-/total-protein 1 
levels in each panel.  Results (A, B) are shown as means ± SEM of data from at least 2 
three separate experiments, each performed with triplicate samples.  The results were 3 
analyzed by ANOVA with Fisher’s post hoc test (A, B).  For each result within a panel, 4 
the values with different superscript letters are significantly different at P < 0.05. 5 
 6 
Fig. 4.  Inhibitory effects of MAPK, NFκB, Stat and Akt pathways on Runx2 and 7 
osteocalcin expression regulated by BMP-2 and TNF-α.  A, B) After preculture, 8 
cells were treated with BMP-4 (100 ng/ml) and TNF-α (10 ng/ml) in the presence or 9 
absence of indicated concentrations of the SAPK/JNK inhibitor SP600125, p38 10 
inhibitor SB203580, ERK inhibitor U0126, JNK/STAT inhibitor AG490, NFκB 11 
activation inhibitor IV and Akt inhibitor SH-5 for 48 h and total cellular RNA was 12 
extracted.  Real-time PCR was performed for quantification of Runx2 and osteocalcin 13 
mRNA levels.  The expression levels of target genes were standardized by RPL19 14 
level in each sample.  Results (A, B) are shown as means ± SEM of data from at least 15 
three separate experiments, each performed with triplicate samples.  The results were 16 
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analyzed by ANOVA with Fisher’s post hoc test (A, B).  For each result within a panel, 1 
the values with different superscript letters are significantly different at P < 0.05. 2 
 3 
Fig. 5.  Possible interaction of BMP-4, TNF-α and PPARs in the regulation of 4 
osteoblast differentiation.  BMP-4 upregulates the expression of PPARα and PPARγ 5 
in C2C12 cells.  A PPARα agonist, but not a PPARγ agonist, upregulates Runx2, 6 
osteocalcin and collagen-1 expression induced by BMP-4 through downregulating 7 
inhibitory Smads (Smad6/7) expression.  On the other hand, the PPARγ agonist 8 
suppressed BMP type-2 receptor (BMPRII) expression, leading to impairment of 9 
BMP-Smad1/5/8 signaling.  TNF-α-induced activation of MAPK, NFκB and Stat 10 
pathways suppresses the BMP-4-induced osteoblast differentiation.  PPARα and 11 
PPARγ agonists reversed suppression by TNF-α of BMP-4-induced osteoblast 12 
differentiation through suppressing SAPK/JNK, NFκB and Stat signaling with reduction 13 
of TNF receptor expression. 14 
 15 
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